All In Biotech

Drug Trial Radar · NCT06545162

Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101

A Randomized, Double-blind, Placebo-controlled, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of CPX101 in Healthy Volunteers and Overweight or Obese Patients With Multiple Doses

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Dec 4, 2024

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled Phase I clinical study was designed to evaluate the tolerability and safety, PK profile, immunogenicity of CPX101 in a single dose in healthy participants and multiple doses in overweight and obese patients, and to initially explore the efficacy of multiple doses in weight loss. The study was divided into two parts: single administration and dose escalation (SAD) and multiple administration and dose escalation (MAD).

Conditions

  • Overweight and Obesity

Interventions

  • CPX101 or placebo 80mg single doseBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 120mg single doseBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 160mg single doseBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 80mg Q2WBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 120mg Q2WBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 160mg Q2WBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 320mg Q2WBiological

    Subcutaneous injection of CPX101 or placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety of CPX101Time frame: Up to 84 days after administration
  2. The tolerability of CPX101Time frame: Up to 84 days after administration
  3. The safety of CPX101Time frame: Up to 196 days after administration
  4. The tolerability of CPX101Time frame: Up to 196 days after administration

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, China

  • Beijing hospital

    Beijing, Beijing Municipality, China

  • Beijing Luhe hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.